Business Context and Reporting Period
This Form 8-K reports on the 2012 Annual Meeting of Stockholders for AcelRx Pharmaceuticals, Inc. (not TalpherA, Inc., as indicated in the metadata), held on July 24, 2012. The filing details the results of shareholder votes on director elections and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding corporate governance events rather than a financial statement.
Material Changes and Voting Results
There were 22,625,000 shares of common stock entitled to vote, with 18,694,714 shares represented at the meeting. The material outcomes were:
- Proposal 1 (Director Elections): Guy P. Nohra, Thomas A. Schreck, and Mark G. Edwards were elected as directors to serve until the 2015 Annual Meeting.
- Guy P. Nohra: 16,889,002 For, 200 Withheld, 1,805,512 Broker Non-Votes.
- Thomas A. Schreck: 16,888,608 For, 594 Withheld, 1,805,512 Broker Non-Votes.
- Mark G. Edwards: 16,889,202 For, 0 Withheld, 1,805,512 Broker Non-Votes.
- Proposal 2 (Auditor Ratification): The selection of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2012, was ratified.
- For: 18,559,957
- Against: 134,757
- Abstain: 0
Stephen J. Hoffman, Richard A. King, and Pamela P. Palmer continue as directors until the 2013 Annual Meeting. Howard B. Rosen and Mark Wan continue until the 2014 Annual Meeting.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the company name is AcelRx Pharmaceuticals, Inc., despite the metadata listing "TALPHERA, INC."
- Confirm the high level of broker non-votes (1,805,512) relative to the total shares entitled to vote.
- Note that the auditor ratification received strong support with only 134,757 votes against.
- Check subsequent filings for the financial performance of the period ending December 31, 2012, as this 8-K contains no financial data.